Spots Global Cancer Trial Database for endocrine therapy
Every month we try and update this database with for endocrine therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer | NCT03204734 | Breast Cancer | Capecitabine endocrine thera... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer | NCT03621904 | Endometrial Can... Endometrial Can... Endometrial Can... | Hormonal Antine... | 18 Years - 110 Years | Radboud University Medical Center | |
| Prognostic and Predictive Factors for Small Breast Tumors | NCT03390608 | Breast Cancer | Endocrine thera... Radiotherapy Herceptin Chemotherapy Type of breast ... Age at diagnosi... Screen detected... Menopausal stat... Tumor size Estrogen recept... Tumor grade HER2-status Intrinsic subgr... Nodal status | - 100 Years | Karolinska Institutet | |
| Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer | NCT04272801 | Breast Cancer F... | tamoxifen, letr... Patient reporte... | 65 Years - | University of Virginia | |
| Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC | NCT04565054 | Breast Cancer F... | Abemaciclib 50 ... | 18 Years - | West German Study Group | |
| Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy | NCT04524728 | Breast Neoplasm Malign... Female | Palbociclib Letrozole 2.5mg Fulvestrant | 18 Years - | Istituti Clinici Scientifici Maugeri SpA | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | NCT03725059 | Breast Cancer | Pembrolizumab (... Placebo (P) Paclitaxel (X) Doxorubicin (A) Epirubicin (E) Cyclophosphamid... Endocrine thera... Radiation thera... Surgery | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | NCT03955939 | Metastatic Brea... | LY3295668 Erbum... Endocrine thera... Midazolam | 18 Years - | Eli Lilly and Company | |
| Brain Health in Breast Cancer Survivors | NCT04297020 | Cognitive Impai... Cognitive Funct... | 35 Years - 65 Years | Jonsson Comprehensive Cancer Center | ||
| A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). | NCT03355157 | Metastatic Brea... | Palbociclib / C... | 18 Years - | German Breast Group | |
| PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer | NCT03621904 | Endometrial Can... Endometrial Can... Endometrial Can... | Hormonal Antine... | 18 Years - 110 Years | Radboud University Medical Center | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer | NCT05306041 | HER2-positive B... | Inavolisib PHESGO Endocrine thera... | 18 Years - | German Breast Group | |
| Application of Radiomics in Breast Cancer | NCT04483804 | Breast Cancer Ultrasound Elastography Pathology Radiomics | Endocrine thera... | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer | NCT03786575 | Breast Neoplasm... Therapeutics Mutation | Next Generation... | 18 Years - | Peking Union Medical College | |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | NCT03955939 | Metastatic Brea... | LY3295668 Erbum... Endocrine thera... Midazolam | 18 Years - | Eli Lilly and Company | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Auricular Acupuncture and Hot Flashes During Adjuvant Endocrine Therapy | NCT06369168 | Hot Flashes | auricular acupu... | 18 Years - 75 Years | Kliniken Essen-Mitte | |
| The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | NCT00097344 | Breast Neoplasm... Neoplasms, Horm... | Atamestane Toremifene Letrozole Aromatase inhib... Estrogen recept... Hormone therapy Endocrine thera... Antiestrogen th... | 18 Years - | Intarcia Therapeutics | |
| Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer | NCT02139774 | Prostate Cancer | Walk with Ease | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | NCT01622361 | Breast Cancer | Adriamycin+Cycl... GnRHa with Tamo... | 20 Years - | Asan Medical Center | |
| Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer | NCT00080613 | Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | exemestane adjuvant therap... aromatase inhib... conventional su... endocrine thera... hormone therapy neoadjuvant the... surgery | - | National Cancer Institute (NCI) | |
| PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | NCT01973660 | Breast Cancer | Lapatinib Trastuzumab Endocrine Thera... Paclitaxel | 18 Years - | SOLTI Breast Cancer Research Group | |
| Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan | NCT05399329 | Breast Cancer | Palbociclib Endocrine thera... | 20 Years - | Pfizer | |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | NCT02057133 | Breast Neoplasm... | LY2835219 Letrozole Anastrozole Tamoxifen Exemestane Everolimus Trastuzumab LY3023414 Fulvestrant Pertuzumab Loperamide Endocrine thera... | 18 Years - | Eli Lilly and Company | |
| Effects of Physical Exercise on Cardio-vascular Efficiency and Quality of Life in Breast Cancer Survivors | NCT04337736 | Breast Cancer F... | Physical exerci... | - 65 Years | ITAB - Institute for Advanced Biomedical Technologies | |
| Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer | NCT05264649 | Arthralgia | acupuncture Guizhi-Shaoyao-... | 20 Years - 90 Years | Show Chwan Memorial Hospital | |
| Application of Radiomics in Breast Cancer | NCT04483804 | Breast Cancer Ultrasound Elastography Pathology Radiomics | Endocrine thera... | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) | NCT04301375 | Mammary Cancer | Pertuzumab and ... Paclitaxel TDM1 Endocrine thera... Omission surger... | 40 Years - | Hospital Clinic of Barcelona | |
| Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer | NCT03045653 | Breast Cancer M... | Tamoxifen Oral ... | 18 Years - 70 Years | Sun Yat-sen University | |
| Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer | NCT03503799 | Primary Invasiv... Estrogen Recept... Human Epidermal... | Observation | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible | NCT03818100 | Breast Cancer | Intensity modul... Endocrine thera... Breast conservi... | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer | NCT03503799 | Primary Invasiv... Estrogen Recept... Human Epidermal... | Observation | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | NCT03573648 | Breast Cancer | Avelumab Endocrine thera... Palbociclib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer | NCT02089854 | Female Breast C... | Toremifene; Ana... | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy | NCT00225758 | Metastatic Brea... | Lapatinib | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer | NCT03204734 | Breast Cancer | Capecitabine endocrine thera... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | NCT02344940 | Breast Cancer | Toremifene Tamoxifen | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | NCT06075953 | Ductal Carcinom... | Tamoxifen Exemestane Letrozole Anastrazole Testosterone + ... Elacestrant Z-endoxifen | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index | NCT01701050 | Metastatic Brea... | Blood collectio... | 18 Years - | Janssen Diagnostics, LLC | |
| Application of Radiomics in Breast Cancer | NCT04483804 | Breast Cancer Ultrasound Elastography Pathology Radiomics | Endocrine thera... | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) | NCT05472792 | Breast Cancer Quality of Life | Accelerated Par... tamoxifen, anas... | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors | NCT03837496 | Breast Cancer Adherence, Medi... | STRIDE Medication Moni... | 21 Months - | Massachusetts General Hospital | |
| TUPKRP Combined With MAB Therapy for LUTS/PCa | NCT03701659 | Advanced Prosta... Lower Urinary T... Quality of Life Overall Surviva... Progression of ... | Surgery combina... Endocrine thera... | 50 Years - 79 Years | The Third Xiangya Hospital of Central South University | |
| Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | NCT06341894 | Early Breast Ca... | Dalpiciclib Endocrine thera... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance | NCT05754528 | Breast Cancer | Standard of car... Dose-frequency ... | 18 Years - | Ottawa Hospital Research Institute | |
| PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) | NCT03809988 | Breast Cancer Advanced Breast... Hormone Recepto... Human Epidermal... | Palbociclib Endocrine thera... | 18 Years - | MedSIR | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer | NCT04134598 | Breast Cancer | Breast irradiat... Endocrine Thera... | 70 Years - | Azienda Ospedaliero-Universitaria Careggi | |
| Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer | NCT02097459 | Breast Cancer | Anastrozole Tamoxifen Toremifene | 45 Years - 55 Years | Peking Union Medical College Hospital | |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | NCT02734615 | Advanced or Met... | LSZ102 LEE011 BYL719 | 18 Years - | Novartis | |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | NCT05919108 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Invasive Breast... | Endocrine Thera... Biopsy of breas... Neratinib Biospecimen Col... Mammogram Magnetic Resona... Breast Surgery Ultrasound | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer | NCT03786575 | Breast Neoplasm... Therapeutics Mutation | Next Generation... | 18 Years - | Peking Union Medical College | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer | NCT04023292 | Breast Neoplasm... | Endocrine thera... Endocrine thera... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer | NCT02580045 | Metastatic Canc... Advanced Cancer Brain Metastasi... | 18 Years - | Duke University | ||
| A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep) | NCT02597868 | Breast Cancer | Capecitabine endocrine thera... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | NCT06369285 | Hormone Recepto... Metastatic Brea... Recurrent Breas... | Alisertib Endocrine thera... | 18 Years - | Puma Biotechnology, Inc. | |
| PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer | NCT03621904 | Endometrial Can... Endometrial Can... Endometrial Can... | Hormonal Antine... | 18 Years - 110 Years | Radboud University Medical Center | |
| Application of Radiomics in Breast Cancer | NCT04483804 | Breast Cancer Ultrasound Elastography Pathology Radiomics | Endocrine thera... | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer | NCT04023292 | Breast Neoplasm... | Endocrine thera... Endocrine thera... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer | NCT04176809 | Breast Cancer | Routine Assessm... | 18 Years - | Centre Georges Francois Leclerc | |
| Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | NCT00921115 | Invasive Breast... | Fulvestrant Anastrazole | 18 Years - | University of Kansas Medical Center | |
| Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer | NCT00525161 | Breast Cancer | sorafenib | 18 Years - | University of Kentucky | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer | NCT03917082 | Breast Cancer F... Hormone Recepto... | Tamoxifen Citra... | 51 Years - | British Columbia Cancer Agency | |
| A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer | NCT02137083 | Metastatic Brea... | Docetaxel Fulvestrant | 18 Years - 70 Years | Fudan University | |
| Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | NCT03671330 | Breast Cancer | Ribociclib Plac... Ribociclib NSAI: Letrozole... Letrozole Goserelin | 18 Years - 60 Years | Novartis | |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | NCT03250676 | Breast Neoplasm... Breast Cancer Estrogen-recept... Cancer, Breast Breast Cancer F... Breast Adenocar... Estrogen Recept... ER Positive | H3B-6545 | 18 Years - | Eisai Inc. | |
| MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ | NCT02352883 | Ductal Breast C... | Magnetic Resona... Therapeutic Con... Therapeutic Sur... Radiation Thera... Endocrine Thera... Quality-of-Life... Laboratory Biom... Cytology Specim... | 18 Years - | Eastern Cooperative Oncology Group | |
| Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer | NCT04352777 | Metastatic Brea... Locally Advance... Hormone Recepto... | Abemaciclib Fulvestrant Aromatase Inhib... | 18 Years - | Duke University | |
| Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | NCT00003517 | Adenocarcinoma ... Stage III Prost... Stage IV Prosta... Recurrent Prost... | antineoplaston ... antineoplaston ... bicalutamide flutamide leuprolide acet... alternative pro... antiandrogen th... biological ther... biologically ba... cancer preventi... complementary a... differentiation... endocrine thera... hormone therapy | 18 Years - | National Cancer Institute (NCI) | |
| The Benefits of Continued Use of Ovarian Function Suppression After 5 Years | NCT06050109 | Breast Cancer F... Endocrine Thera... | OFS continues t... Immunohistochem... | 18 Years - 60 Years | Hubei Cancer Hospital | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
